In addition, FAM167A levels were higher in cells from BCR-ABL-independent imatinib-resistant patients before they received treatment (i.e., at diagnosis), suggesting that expression of FAM167A is predictive of BCR-ABL-independent TKI resistance in CML patients. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.